Abstracts tagged "Outcome measures"

Abstract Number: 2646 • 2015 ACR/ARHP Annual Meeting
Different Wording of the Patient Global Assessment Scale Leads to Different Rating of Disease Activity
Helga Radner¹, Paul Studenic², Stanley B. Cohen³, N Shadick⁴, C Iannaccone⁵, Elisabeth Lie⁶, Maria Dahl Mjaavatten⁶, Meredith Leigh Cohen³, Josef S. Smolen⁷ and Daniel Aletaha⁸, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Division of Rheumatology, Immunology & Allergy, Brigham and Women's Hosp, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of Medicine 3, Division of Rheumatology, Medical Univ Vienna, Vienna, Austria, ⁸Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The patient global assessment of disease activity (PtGA) is a key variable in assessing RA disease activity and remission (REM). Typically assessed on a…
Abstract Number: 649 • 2015 ACR/ARHP Annual Meeting
Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects?
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Amit Chhabra⁴, Heather Jones⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background/Purpose: Psoriatic Arthritis Quality of Life (PsAQol), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related…
Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Edward C. Keystone¹, Philip Baer², J. Antonio Avina-Zubieta³, Anna Jaroszynska⁴, Jude Rodrigues⁵, Regan Arendse⁶, Dalton Sholter⁷, Michael Starr⁸, Ariel Masetto⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, May Shawi¹¹, Allen J Lehman¹² and Susan Otawa¹², ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Burlington, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Rheumatology, CHUS, Fleurimont, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…
Abstract Number: 2335 • 2014 ACR/ARHP Annual Meeting
Reliability and Validity of the Arthritis Helplessness Index in Systemic Sclerosis
Shadi Gholizadeh¹, Sarah D. Mills², Rina S. Fox², Philip J. Clements³, Suzanne Kafaja⁴, Vanessa L. Malcarne⁵, Daniel E. Furst⁶ and Dinesh Khanna⁷, ¹Psychology, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁵Psychology, SDSU/UCSD Joint Doctoral Program in Clinical Psychology; Department of Psychology, San Diego State University, San Diego, CA, ⁶Medicine/ Rheumatology, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁷University of Michigan Health System, Ann Arbor, MI
Background/Purpose: The unpredictable and uncontrollable course of rheumatic diseases has made them an interesting area of study in the learned helplessness and health outcomes literature.…
Abstract Number: 1987 • 2014 ACR/ARHP Annual Meeting
Simulation in Continuing Education: Improving Evidence-Based Decisions for Rheumatoid Arthritis Management
Nimish Mehta¹, Martin Warters² and Douglas Blevins², ¹Medscape, LLC, New York, NY, ²Therasim, Durham, NC
Background/Purpose In many patients with rheumatoid arthritis (RA), the disease is not adequately controlled, and only a minority of patients attain the goal of consistent…
Abstract Number: 1779 • 2014 ACR/ARHP Annual Meeting
Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality
David Solar-Cafaggi¹, Yemil Atisha-Fregoso¹ and Andrea Hinojosa-Azaola², ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: ANCA-associated vasculitides (AAV) are rare, potentially fatal diseases with multiorgan involvement. Evidence for the use of plasmapheresis (PLEX) in patients with severe forms of…
Abstract Number: 1284 • 2014 ACR/ARHP Annual Meeting
Sensitivity to Change of Patient Preference Outcome Measures for Pain in Trials of Patients with Knee Osteoarthritis
Matthew J. Parkes¹, Michael J. Callaghan¹, Terence W. O'Neill¹ and David T. Felson^1,2, ¹Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose A variety of pain and function instruments are often measured in osteoarthritis (OA) clinical trials. Instruments with maximal sensitivity to change are preferred as the…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 572 • 2014 ACR/ARHP Annual Meeting
Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests
Salima F.E. van Weely¹, Joost Dekker^1,2, Martijn P.M. Steultjens³, Christiaan J. Van Denderen¹, Mike T. Nurmohamed¹, Ben A.C. Dijkmans⁴ and Irene E. van der Horst-Bruinsma⁴, ¹Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ²Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ³Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, ⁴Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Physical functioning is considered an important outcome domain for the evaluation of the effectiveness of therapy and the course of the disease. In an effort…
Abstract Number: 416 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient self- monitoring of disease activity may enhance treatment by providing early…
Abstract Number: 383 • 2014 ACR/ARHP Annual Meeting
How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry
Edward C. Keystone¹, Boulos Haraoui², John Kelsall³, Carter Thorne⁴, Philip Baer⁵, William Bensen⁶, Denis Choquette⁷, Regan Arendse⁸, Dalton Sholter⁹, Niall Jones¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, May Shawi¹³, Allen J Lehman¹⁴ and Susan Otawa¹⁴, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Montreal Hospital Centre, Montreal, QC, Canada, ³The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹194 Main Street, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Composite measures of disease activity can facilitate clinical decision-making to achieve treatment goals, and treating-to-target has been shown to improve outcomes. Both CRA and…
Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Arthritis Research Centre of Canada, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…
Abstract Number: 58 • 2014 ACR/ARHP Annual Meeting
What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
Sandra Tälli¹, Adrien Etcheto², Bruno Fautrel³, Andra Balanescu⁴, Jürgen Braun⁴, Juan D. Cañete⁵, Kurt de Vlam⁴, Maarten de Wit⁴, Turid Heiberg⁴, Philip S. Helliwell⁴, Umut Kalyoncu⁴, Uta Kiltz⁶, Mara Maccarone⁴, Dora Niedermayer⁴, Kati Otsa⁴, Rossana Scrivo⁴, Josef Smolen⁴, Tanja Alexandra Stamm⁴, Douglas J. Veale⁷, Tore K. Kvien⁴ and Laure Gossec³, ¹Rheumatology, GRC UPMC Paris 06 University, Pitie-Salpétriere hospital, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴PsAID taskforce, EULAR, Zurich, Switzerland, ⁵Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Patient global assessment (PGA) is one of the most widely used patient reported outcomes (PROs) in psoriatic arthritis (PsA). PGA should reflect the global…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].